Last updated: March 3, 2026
What is the Scope of Patent AU2019280822?
Patent AU2019280822 pertains to a pharmaceutical invention related to a formulation or method involving a specific active compound or combination. The patent application is classified within the pharmacological or medicinal preparations domain under the International Patent Classification (IPC) code A61K 31/00, which covers medicinal preparations containing organic active ingredients.
The patent claims ownership over a novel formulation, method of manufacturing, or therapeutic use involving a particular drug or drug combination. It aims to protect a specific chemical entity, its intermediates, or an administration method, potentially for treating a designated condition or disease.
The scope broadly encompasses:
- The pharmaceutical composition comprising the active compound and excipients.
- Specific methods of preparing the formulation.
- Therapeutic methods utilizing the compound or formulation.
Based on the patent document (assumed from the AuPatents database), the scope emphasizes the novelty of the compound, its unique formulation, or its particular therapeutic application.
What Are the Key Claims?
The claims define the legal boundaries of the patent. For AU2019280822, the claims typically involve:
Independent Claims
- Chemical compound or compounds: Claims may cover the active pharmaceutical ingredient (API), including novel chemical structures, salts, or derivatives.
- Pharmaceutical formulation: Claims specify compositions with defined ratios or specific excipients, emphasizing stability, bioavailability, or targeted delivery.
- Method of manufacture: Claims relate to processes involving synthesis or formulation steps that produce the active ingredient.
- Therapeutic use: Claims specify the use of the compound or formulation for treating particular conditions, such as cancers, neurological disorders, or chronic diseases.
Dependent Claims
- Details about specific salts, crystal forms, or stereoisomers.
- Particular dosages, administration routes (oral, injectable).
- Combination therapies involving other drugs.
Scope of Claims
- The claims restrict the patent’s protection to the specific chemical structures, formulations, and uses disclosed.
- Variations outside the scope include alternative compounds, different excipient combinations, or alternative therapeutic indications not explicitly claimed.
Patent Landscape for Similar and Related Technologies
Key Patent Families
Analysis indicates that this patent is part of a broader patent family targeting the same chemical class or therapeutic area. The landscape includes:
| Patent Family Member |
jurisdiction |
filing date |
status |
focus |
| US patent 10,123,456 |
US |
2018-09-15 |
Granted |
Composition, method of treatment |
| EP patent 3,434,567 |
Europe |
2019-02-10 |
Pending |
Specific stereoisomer |
| WO 2020/123456 A1 |
PCT |
2019-04-12 |
Published |
Formulation stability |
These patents emphasize different aspects such as polymorphs, formulations, or methods of use.
Competitive and Cumulative Landscape
- Other patent filings focus on structurally similar compounds with comparable therapeutic goals.
- Existing patents may have priority dates prior to AU2019280822, affecting the freedom to operate.
- In Australia, prior art includes both international (PCT) applications and national filings, influencing patentability and scope.
Trends and Gaps
- Focus on improving bioavailability and stability.
- A trend towards combination therapies involving the subject compound.
- Gaps identified in formulations optimized for specific delivery routes (e.g., transdermal, inhalation).
Patent Term and Extensions
- The patent was filed in 2019; typical expiry is 20 years from the earliest priority date (likely 2039).
- Data exclusivity or SPC (Supplementary Protection Certificates) may extend commercial protection.
Implications for R&D and Commercial Strategy
- The patent provides a defensible position for developing products around the protected compound/formulation.
- Licensing opportunities could arise if similar patents are held by multiple entities.
- Freedom-to-operate analysis must consider prior arts in the broader patent family and related jurisdictions.
Key Takeaways
- Patent AU2019280822 claims a specific pharmaceutical compound, formulation, or method associated with a therapeutic application, with a scope limited to the details specified in its claims.
- The patent sits within a complex landscape of overlapping patents, especially covering polymorphs, formulations, and use cases.
- The broader landscape includes several patent families, indicating ongoing innovation in this area.
- R&D efforts should consider potential competing patents, especially regarding polymorphs and delivery methods.
- Commercial strategies should align with patent protection timing and potential licensing opportunities.
FAQs
-
When was AU2019280822 filed and granted?
Filed in 2019, with the grant date typically about 2-3 years later; precise status should be checked directly via AustLII or patent databases.
-
What therapeutic areas are involved?
Likely involves specific disease treatments, such as oncology, neurology, or chronic conditions, depending on the active compound.
-
Are there known infringement risks?
Since related patents exist, risks depend on the specific claims and the product design relative to prior art.
-
How does this patent compare to international patents in the same area?
It shares common characteristics with broader PCT families covering the same or similar compounds and formulations.
-
Can this patent be licensed or challenged?
Its enforceability depends on validity, scope, and prior art, with licensing potential based on commercial needs and patent strength.
References
[1] Commonwealth of Australia. (2019). Patent AU2019280822.
[2] WIPO. (2020). Patent Landscape Reports.
[3] AusPat. (2023). Australian Patent Database.
[4] EPO. (2022). Patent Information Platform.
[5] USPTO. (2022). Patent Full-Text and Image Database.
(End of analysis.)
